The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 2 rounds in the feed, most often in Biotech.
We are dedicated to making medicines that cure or transform the clinical management of serious and life-threatening diseases.
Venture capitalNew York City, USAscionlifesciences.comRounds from 2026-11-17 to 2026-11-17
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Marrow Therapeutics An experimental treatment for sickle cell disease and beta thalassemia that aims to deliver genetic medicines directly to bone marrow cells. | Series B contradicted | $120M | 2026-11-17 | [ PART ] |
Marrow Therapeutics An experimental treatment for sickle cell disease and beta thalassemia that aims to deliver genetic medicines directly to bone marrow cells. | Series A |
| $173M |
| 2026-11-17 |
| [ LEAD ] |